Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

The Oncologist
Germán Reyes-BoteroJean-Yves Delattre

Abstract

Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status.Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study. The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) <70 is not established. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged ≥70 years and a KPS <70. Patients aged ≥70 years with a KPS <70 and biopsy-proven GBM were eligible for this multicenter, prospective, nonrandomized, phase II trial of older patients with impaired performance status. Treatment consisted of TMZ administered at 130-150 mg/m2 per day for 5 days every 4 weeks plus Bev administered at 10 mg/kg every 2 weeks. The trial included 66 patients (median age of 76 years; median KPS of 60). The median overall survival (OS) was 23.9 weeks (95% confidence interval [CI], 19-27.6), and the median progression-free survival (PFS) was 15.3 weeks (95% CI, 12.9-19.3). Twenty-two (33%) patients...Continue Reading

References

Mar 15, 1997·Cancer·A FleuryJ Y Delattre
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 13, 2007·The New England Journal of Medicine·Florence Keime-GuibertUNKNOWN Association of French-Speaking Neuro-Oncologists
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Jun 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaime Gállego Pérez-LarrayaJean-Yves Delattre
May 15, 2012·The Lancet Oncology·Wolfgang WickUNKNOWN NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Sep 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wilson RoaElena Fidarova

❮ Previous
Next ❯

Citations

Mar 24, 2020·The Cochrane Database of Systematic Reviews·Catherine HannaRobin Grant
Apr 16, 2020·Cancers·Vilashini RajaratnamShama Parveen Mirza
Mar 13, 2019·Cancers·Giuseppe MinnitiSergio Paolini
Oct 14, 2020·Cell Biology International·S Daisy PrecillaAnitha Thirugnanasambandhar Sivasubramanian
Jan 20, 2021·The Journal of Clinical Investigation·Rohit SharmaVamsi K Mootha
Dec 20, 2020·Pharmaceuticals·Yusuke FunakoshiMasahiro Mizoguchi
May 1, 2021·Cancers·Elisabete Cruz Da SilvaLaurence Choulier
Jul 20, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hui YaoYulun Huang
Apr 21, 2020·Revue neurologique·F Laigle-Donadey, S Greffard

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SAS

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.